A compound is represented by one of formulae (11) to (13). R.sub.1 to R.sub.4 each independently represent a group represented by a formula (1-1) or the like, or a group represented by a formula (2-1), a group represented by a formula (2-2) or the like. At least one of R.sub.1 to R.sub.4 is the group represented by the formula (1-1) or the like. At least one of R.sub.1 to R.sub.4 is the group represented by the formula (2-1), (2-2) or the like. For instance, X.sub.1 represents an oxygen atom, a sulfur atom, or CR.sub.151R.sub.152, R.sub.101 to R.sub.110 and R.sub.151 and R.sub.152 each independently representing a hydrogen atom or a substituent. For instance, R.sub.161 to R.sub.168 and R.sub.171 and R.sub.180 each independently represent a hydrogen atom or a substituent. * each independently represents a bonding position to a carbon atom in a benzene ring in each of formulae (11) to (13): ##STR00001##

The invention relates to organic electroluminescence devices containing indone carbazole derivatives.

The invention relates to organic electroluminescence devices containing indone carbazole derivatives.

A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, β-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.).

##STR00001##

The present disclosure provides substituted indole compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R.sup.1a, R.sup.1e, G1, G2, Q.sup.1, Q.sup.2, Q.sup.3, and (II) are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.

##STR00001##

The present invention relates to methods for preparing 5-fluoro-4-(7′-fluoro-2′-methylspiro[cyclopentane-1,3′-indol]-5′-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine and a salt and an intermediate thereof The methods provided herein have improved the existing synthesis methods, simplified the preparation process and increased the yield and purity, and can well meet the requirement of large-scale industrial manufacture.

The present invention relates to methods for preparing 5-fluoro-4-(7′-fluoro-2′-methylspiro[cyclopentane-1,3′-indol]-5′-yl)-N-(5-(1-methylpiperidin-4-yl)pyridin-2-yl)pyrimidin-2-amine and a salt and an intermediate thereof The methods provided herein have improved the existing synthesis methods, simplified the preparation process and increased the yield and purity, and can well meet the requirement of large-scale industrial manufacture.

The present invention provides a method for synthesizing a 3-spiro three-membered ring indolinone derivative, which comprises under a protective atmosphere, reacting a 3-indol-ethanol compound as a reaction raw material at 20-60° C. in the presence of an additive and an organic base in an organic solvent, to obtain a 3-spiro three-membered ring indolinone compound after the reaction is complete. The additive is N-bromosuccinimide (NBS) or N-chlorosuccinimide (NCS). The method of the present invention does not require a metal catalyst, and the 3-spiro three-membered ring indolinone derivative is synthesized in one step in the presence of NBS or NCS. The reaction conditions are mild, the operations are simple and safe, and the yield is high.

The present invention provides a method for synthesizing a 3-spiro three-membered ring indolinone derivative, which comprises under a protective atmosphere, reacting a 3-indol-ethanol compound as a reaction raw material at 20-60° C. in the presence of an additive and an organic base in an organic solvent, to obtain a 3-spiro three-membered ring indolinone compound after the reaction is complete. The additive is N-bromosuccinimide (NBS) or N-chlorosuccinimide (NCS). The method of the present invention does not require a metal catalyst, and the 3-spiro three-membered ring indolinone derivative is synthesized in one step in the presence of NBS or NCS. The reaction conditions are mild, the operations are simple and safe, and the yield is high.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.